Evidence map›Paper›PMID 25348621›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques.

Tsuyoshi Fujita, Benjamin J Burwitz, Glen M Chew, Jason S Reed, Reesab Pathak, Elizabeth Seger, Kiera L Clayton, James M Rini, Mario A Ostrowski, Naoto Ishii and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Upregulation of Multiple CD8Journal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Impact of Myeloid Reservoirs in HIV Cure Trials.Current HIV/AIDS reports · 2019
    Review
  13. Review
  14. Review
  15. Strategies to target non-T-cell HIV reservoirs.Current opinion in HIV and AIDS · 2016
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Tsuyoshi FujitaDepartment of Tropical Medicine, Hawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii, Manoa, HI 96813; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan;
Benjamin J BurwitzVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006;
Glen M ChewDepartment of Tropical Medicine, Hawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii, Manoa, HI 96813;
Jason S ReedVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006;
Reesab PathakVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006;
Elizabeth SegerVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006;
Kiera L ClaytonDepartment of Immunology, University of Toronto, Toronto, Ontario M5S 1A8, Canada; and.
James M RiniDepartment of Immunology, University of Toronto, Toronto, Ontario M5S 1A8, Canada; and.
Mario A OstrowskiDepartment of Immunology, University of Toronto, Toronto, Ontario M5S 1A8, Canada; and.
Naoto IshiiDepartment of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan;
Marcelo J KurodaDivision of Immunology, Tulane National Primate Research Center, Covington, LA 70433.
Scott G HansenVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006;
Jonah B SachaVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006; lndhlovu@hawaii.edu sacha@ohsu.edu.
Lishomwa C NdhlovuDepartment of Tropical Medicine, Hawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii, Manoa, HI 96813; lndhlovu@hawaii.edu sacha@ohsu.edu.
Children's Cancer Therapy Development Institute · USUniversity of Toronto · CAOregon Health & Science University · USTohoku University · JPUniversity of Hawaiʻi at Mānoa · USOregon National Primate Research Center · USTulane University · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5M
NIAID NIH HHS AI027757NIAID NIH HHS AI096109NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS U19 AI096109NIH HHS P51 OD011092NIH HHS P51 OD011104PHS HHS P30 A1027763
6 · The paper itself

Abstract

The T cell Ig- and mucin domain-containing molecule-3 (Tim-3) negative immune checkpoint receptor demarcates functionally exhausted CD8(+) T cells arising from chronic stimulation in viral infections like HIV. Tim-3 blockade leads to improved antiviral CD8(+) T cell responses in vitro and, therefore, represents a novel intervention strategy to restore T cell function in vivo and protect from disease progression. However, the Tim-3 pathway in the physiologically relevant rhesus macaque SIV model of AIDS remains uncharacterized. We report that Tim-3(+)CD8(+) T cell frequencies are significantly increased in lymph nodes, but not in peripheral blood, in SIV-infected animals. Tim-3(+)PD-1(+)CD8(+) T cells are similarly increased during SIV infection and positively correlate with SIV plasma viremia. Tim-3 expression was found primarily on effector memory CD8(+) T cells in all tissues examined. Tim-3(+)CD8(+) T cells have lower Ki-67 content and minimal cytokine responses to SIV compared with Tim-3(-)CD8(+) T cells. During acute-phase SIV replication, Tim-3 expression peaked on SIV-specific CD8(+) T cells by 2 wk postinfection and then rapidly diminished, irrespective of mutational escape of cognate Ag, suggesting non-TCR-driven mechanisms for Tim-3 expression. Thus, rhesus Tim-3 in SIV infection partially mimics human Tim-3 in HIV infection and may serve as a novel model for targeted studies focused on rejuvenating HIV-specific CD8(+) T cell responses.

Indexed as

Acquired Immunodeficiency SyndromeAmino Acid SequenceAnimalsCD8-Positive T-LymphocytesCell ProliferationCells, CulturedCytotoxicity, ImmunologicDisease Models, AnimalGene Expression RegulationHepatitis A Virus Cellular Receptor 2HumansImmunologic MemoryImmunotherapyMacaca mulattaMembrane ProteinsMolecular Sequence DataHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Membrane ProteinsProgrammed Cell Death 1 Receptor

Identifiers

PMID25348621
PMCPMC4239185
OpenAlexW1953898917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.